Clinical trials: Stroke Treatment
Ischaemic Stroke
SITS-IVT in Patients >80 Years Study
A non-interventional post-approval study on Safe Implementation of Treatment in Stroke - International Stroke Thrombolysis Register (SITS-ISTR) existing data of intravenous recombinant tissue plasminogen Activator (rt-PA) (0.9…
- Trial name
- SITS_ELDERLY (NCT04260347)
- Testing
- Alteplase
- Where
- Sweden
- Volunteers
- 1,655 people
- Sponsor
- Boehringer Ingelheim
Acute Ischemic Stroke
AXIS 2: AX200 for the Treatment of Ischemic Stroke
The purpose of this study is to assess the efficacy of AX200 (filgrastim) in the treatment of acute ischemic stroke and to assess the safety and tolerability of AX200.
- Trial name
- AXIS-2 (NCT00927836)
- Testing
- Filgrastim, Sodium chloride solution
- Where
- 58 sites in Austria, Belgium and 5 more
- Volunteers
- 328 people
- Sponsor
- Sygnis Bioscience GmbH & Co KG
Stroke
Cytoflavin in the Complex Rehabilitation of Stroke Patients
It is known that the acute period of stroke occurs is accompanied by oxidative stress, when intense generation of reactive oxygen species (ROS) have a toxic effect, which causes oxidative degradation of proteins, lipids, nucleic…
- Trial name
- NCT05935787
- Testing
- Cytoflavin (Inosine + Nicotinamide + Riboflavin + Succinic Acid)
- Where
- 3 sites in Russia
- Volunteers
- 240 people
- Sponsor
- POLYSAN Scientific & Technological Pharmaceutical Company
Atrial Fibrillation
Patient Convenience Study- NIS RELATE
The aim of this non-interventional study is to describe patient's perception of anticoagulant treatment when using Pradaxa® to prevent stroke and systemic embolism while suffering from atrial fibrillation (according to its…
- Trial name
- NCT02849509
- Testing
- Pradaxa (dabigatran), Vitamin K antagonist
- Where
- 50 sites in Indonesia, Malaysia and 3 more
- Volunteers
- 1,313 people
- Sponsor
- Boehringer Ingelheim
Nervous System Disorders
Dysport® Adult Upper Limb Spasticity
The purpose of this research study is to assess the efficacy of Dysport compared to placebo in improving muscle tone in hemiparetic subjects with upper limb spasticity due to stroke or traumatic brain injury.
- Trial name
- NCT01313299
- Testing
- Botulinum toxin type A
- Where
- 40 sites in United States, Belgium and 7 more
- Volunteers
- 243 people
- Sponsor
- Ipsen
AIS
A Multicentre, Randomised, Double-blind, Placebo-parallel Controlled Phase Ⅲ Clinical Trial Evaluating the Efficacy and Safety of BXOS110 Injection in the Treatment of Acute Ischaemic Stroke Within 3 Hours of Onset.
The purpose of this study was to evaluate the efficacy of early administration of BXOS110 for injection in reducing overall disability in patients with acute ischaemic stroke
- Trial name
- NCT07520565
- Testing
- BXOS110
- Where
- 9 sites in China
- Volunteers
- 1,112 people
- Sponsor
- Biocells (Beijing) Biotech Co.,Ltd
Atrial Fibrillation
Real-world Comparative Effectiveness of Stroke Prevention in Patients With Atrial Fibrillation Treated With Factor Xa Non-vitamin-K Oral Anticoagulants (NOACs) vs. Phenprocoumon
Existing real-world studies have provided evidence that novel oral anticoagulants (NOACs) in general and rivaroxaban in particular are more effective and at least as safe as warfarin in non-valvular atrial fibrillation (NVAF)…
- Trial name
- ReLoaDeD (NCT03563937)
- Testing
- Phenprocoumon, Apixaban, Rivaroxaban (Xarelto, BAY59-7939)
- Where
- Germany
- Volunteers
- 64,920 people
- Sponsor
- Bayer
Stroke, Muscle Spasticity
Safety Study of Botulinum Toxin Type A for the Treatment of Focal Upper Limb Poststroke Spasticity
The purpose of this study is to evaluate the safety of repeated doses of Botulinum Toxin Type A for the treatment of focal upper limb poststroke spasticity
- Trial name
- NCT00651729
- Testing
- Botulinum Toxin Type A
- Where
- 2 sites in United States, Canada
- Volunteers
- 279 people
- Sponsor
- Allergan
Acute Ischemic Stroke
Safety, Tolerability, and Preliminary Efficacy of HRS-7450 Injection in the Treatment of Acute Ischemic Stroke: a Multi-center, Randomized, Double-blind, Double-dummy, Placebo-controlled Clinical Trial
This study is a multi-center, randomized, double-blind, double-dummy, placebo-controlled, single dose escalation study aimed at evaluating the overall safety, tolerability, and preliminary efficacy of HRS-7450 in patients with…
- Trial name
- NCT06447415
- Testing
- HRS-7450, 0.9% sodium chloride injection
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Ischemic Stroke
EMAGINE 2.0 - Electromagnetic Field Ischemic Stroke - Novel Subacute Treatment
This is a multicenter study that will be conducted at approximately 20 centers and up to 30 centers, if the sample size will be increased following interim assessment.
- Trial name
- NCT06386874
- Testing
- Q Therapeutic System (BQ 3.0) - Active
- Where
- 14 sites in United States
- Volunteers
- 122 people
- Sponsor
- BrainQ Technologies Ltd.
Spasticity, Cerebrovascular Accident
Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb Spasticity
Phase 2/3, randomized, double-blind, placebo-controlled, single-treatment, multicenter trial assessing the efficacy and safety of MYOBLOC for the treatment of upper limb spasticity in adults followed by an open-label extension…
- Conditions
- Spasticity, Cerebrovascular Accident, Multiple Sclerosis, Traumatic Brain Injury
- Trial name
- NCT04815967
- Testing
- Phase 2; Low Dose MYOBLOC (10,000 Units), Phase 2; High Dose MYOBLOC (20,000 Units), Phase 3; MYOBLOC
- Where
- 9 sites in United States, Hungary and 1 more
- Volunteers
- 32 people
- Sponsor
- Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC
Acute Coronary Syndrome, Venous Thrombosis
Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden)
This prospective cohort study will provide information about: Characteristics of Rivaroxaban use in patients who are prescribed Rivaroxaban for the first time compared to patients who are prescribed standard of care for the first…
- Conditions
- Acute Coronary Syndrome, Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation
- Trial name
- NCT02468102
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Standard of care drugs
- Where
- Sweden
- Volunteers
- 99,999 people
- Sponsor
- Bayer
Heat Stroke
Efficacy and Safety of Ryanodex® (EGL-4104) as Adjuvant Treatment in Subjects With Exertional Heat Stroke (EHS)
Study EGL-4104-C-1502 is a phase 2, single-site, open-label, randomized, 2-arm parallel study of Ryanodex for the adjuvant treatment of exertional heat stroke (EHS) administered intravenously (IV), to current standard of care…
- Trial name
- NCT02513095
- Testing
- Dantrolene sodium for injectable suspension
- Where
- Saudi Arabia
- Volunteers
- 34 people
- Sponsor
- Eagle Pharmaceuticals, Inc.
Stroke, Atrial Fibrillation
GLORIA-AF Registry Program (Phase II/III)
In this part of the Registry Program patients with non-valvular atrial fibrillation (AF) at risk for stroke are enrolled to characterize the target population and to collect real world data on important outcome events.
- Trial name
- NCT01937377
- Where
- 5 sites in Switzerland
- Volunteers
- 200 people
- Sponsor
- Boehringer Ingelheim
Hemorrhagic Stroke, Aneurysm, Intracranial
The Use of p48/64 MW HPC Flow Modulation Device in the Treatment of Wide-necked Intracranial Aneurysms
To determine safety and effectiveness of the p48 MW HPC and p64 MW HPC Flow Modulation Device in the treatment of wide-necked intracranial aneurysms.
- Conditions
- Hemorrhagic Stroke, Aneurysm, Intracranial, Saccular Aneurysm, Fusiform Aneurysm
- Trial name
- PIANO (NCT07143019)
- Testing
- Flow diversion
- Where
- 25 sites in United States
- Volunteers
- 214 people
- Sponsor
- phenox Inc.
Nervous System Disorders
Dysport® Adult Upper Limb Spasticity Extension Study
The purpose of this research study is to assess the long term safety of Dysport® in hemiparetic subjects with upper limb spasticity due to stroke or traumatic brain injury over repeated treatment cycles.
- Trial name
- NCT01313312
- Testing
- Botulinum toxin type A
- Where
- 34 sites in United States, Belgium and 7 more
- Volunteers
- 258 people
- Sponsor
- Ipsen
Stroke, Cerebrovascular Accident
AMES Treatment of the Impaired Leg in Chronic Stroke Patients
The purpose of this protocol is to determine if individuals who had a stroke more than one year before entering the study and whose ankles remain substantially impaired are able to sense and move the affected leg better after…
- Conditions
- Stroke, Cerebrovascular Accident, Hemiparesis
- Trial name
- AMES (NCT01378637)
- Testing
- AMES- Leg treatment
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- AMES Technology
Chronic Ischemic Stroke
CC-101 (f/k/a NR1) Neural Stem Cell Transplantation for Adults With Chronic Ischemic Stroke
The suNR1se II Study is a Phase 2b randomized, controlled, multi-center clinical trial evaluating the efficacy and safety of stereotactic intracerebral administration of CC-101 (f/k/a NR1), an investigational allogeneic neural…
- Trial name
- suNR1se II (NCT07709845)
- Testing
- CC-101 (f/k/a NR1) Intracerebral Transplantation, Tacrolimus
- Volunteers
- 36 people
- Sponsor
- Clarion Cells, Inc.
Atrial Fibrillation
Satisfaction/Quality of Life With Rivaroxaban in SPAF (Stroke Prevention in Atrial Fibrillation) Indication
National, multicenter, prospective, observational, non-interventional study. The objective is to determine if the switch from Vitamin K antagonists (VKA) to Xarelto in subjects treated with VKA with issues for stroke prevention…
- Trial name
- SAFARI (NCT01805531)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- France
- Volunteers
- 411 people
- Sponsor
- Bayer
Acute Ischemic Stroke
Study to Assess the Efficacy and Safety of QHRD106 Injection in Acute Ischemic Stroke.
The purpose of this study is to determine the efficacy and safety of QHRD106 injection in treating acute ischemic stroke.
- Trial name
- NCT07396337
- Testing
- QHRD106 Injection (Low-dose group), QHRD106 Injection (Middle-dose group), QHRD106 Injection (High-dose group)
- Where
- China
- Volunteers
- 320 people
- Sponsor
- Changzhou Qianhong Bio-pharma Co., Ltd.